← Back to Clinical Trials
Recruiting NCT05905419

NCT05905419 Neuroimaging of Opioid Phase (OPAL)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05905419
Status Recruiting
Phase
Sponsor Duke University
Condition Chronic Pain
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2023-06-01
Primary Completion 2027-06-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Opioid Phase

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2023-06-01 with a primary completion date of 2027-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to compare activity in the brains of female adults with chronic pain and/or opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.

Eligibility Criteria

Inclusion Criteria for Healthy Controls: 1. female and ages 18+ 2. ability to read/understand English and give consent to participate 3. no current or history of chronic pain 4. not regularly taking any pain-relieving or mood-altering medications (per PI discretion) 5. absence of use of opioid medications Inclusion Criteria for Individuals with Chronic Pain: 1. female and ages 18 + 2. ability to read/understand English and give consent to participate 3. self-reported or physician diagnosis of fibromyalgia and/or chronic pain 4. current use of opioid medication(s) for inclusion in the opioid patient group -OR- absence of use of opioid medications for inclusion in the non-opioid patient group Exclusion Criteria (for both groups): 1. limited ability to participate fully in behavioral tasks, longitudinal follow-up 2. MRI contraindication 3. any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study 4. male

Contact & Investigator

Central Contact

HAPN Lab Manager

✉ chronicpainresearch@duke.edu

📞 919-684-2758

Principal Investigator

Katherine T Martucci, PhD

PRINCIPAL INVESTIGATOR

Duke University

Frequently Asked Questions

Who can join the NCT05905419 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05905419 currently recruiting?

Yes, NCT05905419 is actively recruiting participants. Contact the research team at chronicpainresearch@duke.edu for enrollment information.

Where is the NCT05905419 trial being conducted?

This trial is being conducted at Durham, United States.

Who is sponsoring the NCT05905419 clinical trial?

NCT05905419 is sponsored by Duke University. The principal investigator is Katherine T Martucci, PhD at Duke University. The trial plans to enroll 140 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology